Health Care · Wholesale-Drugs, Proprietaries & Druggists' Sundries

CAH Cardinal Health SEC Filings & Insider Trading Activity 2026

company
CIK 721371125 filings
S&P 500

CAH at a glance

Cardinal Health (CAH, SEC CIK 721371) filed its latest 10-K annual report on August 11, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended June 30, 2026 (FY2026), Cardinal Health (CAH) reported revenue of $254.2 billion (up 14.2% from FY2025) and net income of $1.7 billion. Diluted EPS was $7.23.
  • As of September 30, 2026, 49 institutional investment managers tracked by SignalX reported holding Cardinal Health (CAH) shares worth $22.5 billion in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2026
$254.2B
+14.2% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
49 funds
$22.5B · −2 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 5.07

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Jun 30, 2026

Full analysis →

Management Discussion & Analysis

  • Revenue $254.2B, up 14% YoY; Pharma segment up 15% to $234.8B, GMPD flat at $12.7B, Other +26% to $6.8B
  • Operating margin approx. 1.03% ($2.613B / $254.2B) GAAP operating earnings up 15%, Non-GAAP margin 1.43% ($3.624B), Non-GAAP operating earnings up 30%
  • Best segment: Pharma profit $2.783B up 23%; Worst: GMPD profit $258M up 91% but lowest dollar profit among segments
  • Cash flow: Operating cash flow $5.2B; Capex $649M; Dividends $491M; Share repurchases $1.4B; Solaris Health acquisition $1.9B; New long-term debt net $1B; Cash and equivalents $4.9B
  • Forward outlook: Management warns of tariff-related risks, regulatory uncertainties on branded pharma pricing, moderating GLP-1 demand, expects FY27 capex ~$700M, new $5B share repurchase program authorized

Risk Factors

  • DOJ Civil Investigative Demand November 2023 for potential Anti-Kickback Statute and False Claims Act violations in 2022 acquisition
  • $200M IEEPA tariffs paid on GMPD segment goods with $200M receivable recorded in Q4 FY26 for expected U.S. Government refund
  • FDA April 2024 warning letter on plastic syringes from Chinese manufacturer lacking 510(k) clearance, requiring corrective actions
  • Competitive pressure from healthcare industry consolidation risking customer loss due to greater negotiating power of combined enterprises
  • IRS tax audit challenging CARES Act self-insurance losses risking $400M additional tax expense plus $1.4B liability for 2015-2020 fiscal years

AI summary of the CAH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Mar 31, 2026

Risk Factors

  • No risk-factor text provided; only filing index and signatures included

AI summary of the CAH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All 11 director nominees reelected for one-year terms, with votes supporting each nominee exceeding 176 million
  • Say-on-pay approved on an advisory basis, with 173,487,665 votes for and 8,501,886 against
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Cardinal Health announced fiscal Q1 2026 results for the quarter ended September 30, 2026
  • Detailed financial results and management commentary are contained in Exhibit 99.1

Item 7.01: Regulation FD Disclosure

  • Webcast covers quarter ended September 30, 2026 results and fiscal 2027 outlook
  • CEO and CFO presentation scheduled for November 5, 2026 at 8:30 a.m. Eastern time

Item EX-99.1: Item EX-99.1

  • Q1 FY27 revenue $67.5B, up 5%; non-GAAP EPS $3.26, up 28%, signaling strong operating momentum
  • Pharmaceutical and Specialty Solutions profit $783M, up 17%, while GMPD profit fell 28% to $33M
Filed Oct 1, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Binding letter of intent extends pharmaceutical distribution agreements with CVS Health through June 2032
  • Long-duration CVS relationship provides visibility into Cardinal Health’s distribution revenue

AI summaries of CAH 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CAH

Don't miss the next CAH filing

  • Alerts as it files. A push when CAH files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CAH, by share count.
  • Ask anything. An AI agent that reads every CAH filing and answers with sources.

CAH alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Killefer NancyANov 12, 2026-
Ramakrishna SudhakarANov 12, 2026-
Evans David CANov 12, 2026-
Musslewhite Robert WANov 12, 2026-
Azelby RobertANov 12, 2026-
Hall Patricia HemingwayANov 12, 2026-
Brennan MichelleANov 12, 2026-
Edison Sheri H.ANov 12, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Revenue-$222.6B$254.2B
Gross Profit-$8.2B$9.8B
Operating Income-$2.3B$2.6B
Net Income-$1.6B$1.7B
Gross Margin-3.7%3.8%
Op. Margin-1.0%1.0%
Net Margin-0.7%0.7%
Balance Sheet
Total Assets$45.1B$53.1B$57.3B
Equity--$2.8B-$2.9B
ROE--56.1%-59.5%
Per Share
EPS-$6.45$7.23
Cash Flow
Operating CF-$2.4B$5.2B
CapEx$511.0M$547.0M$649.0M

Source: XBRL data in Cardinal Health (CAH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CAH share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CAH shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202649$22.47B
Q2 202651$24.45B
Q1 202648$22.85B
Q4 202548$22.71B
Q3 202550$18.67B
Q2 202547$19.43B
Q1 202544$11.65B
Q4 202441$8.97B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 378 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CAH filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 16, 2026--
8-KNov 16, 2026Analysis-
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 16, 2026--
10-QNov 5, 2026-
8-KNov 5, 2026Analysis-
8-KOct 1, 2026Analysis-
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--

Related Health Care companies

All Health Care →

CAH SEC filings: frequently asked questions

Which institutions hold CAH stock?

As of September 30, 2026, the largest Cardinal Health (CAH) holders among the 13F filers tracked by SignalX were BlackRock ($5.7 billion), Vanguard Capital Management LLC ($3.4 billion), Vanguard Portfolio Management LLC ($3.0 billion), State Street Corp ($2.7 billion), Morgan Stanley ($1.1 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CAH's revenue in fiscal year 2026?

For the fiscal year ended June 30, 2026 (FY2026), Cardinal Health (CAH) reported revenue of $254.2 billion (up 14.2% from FY2025) and net income of $1.7 billion. Diluted EPS was $7.23. The figures come from the XBRL data in the 10-K.

What are the main risks in CAH's latest 10-K?

In the 10-K filed August 11, 2026, Cardinal Health (CAH) flagged: DOJ Civil Investigative Demand November 2023 for potential Anti-Kickback Statute and False Claims Act violations in 2022 acquisition. $200M IEEPA tariffs paid on GMPD segment goods with $200M receivable recorded in Q4 FY26 for expected U.S. Government refund. (AI summary of the Risk Factors section.)

What did CAH report in its latest 8-K?

Cardinal Health (CAH) filed an 8-K on November 16, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). All 11 director nominees reelected for one-year terms, with votes supporting each nominee exceeding 176 million.

What are the latest CAH SEC filings?

Cardinal Health (CAH) filed its latest 10-K annual report on August 11, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 16, 2026.

What is CAH's SEC CIK number?

Cardinal Health (CAH)'s SEC Central Index Key (CIK) is 721371. EDGAR lists every CAH filing under that number.

Ask anything about CAH

The research agent reads CAH's filings, financials, insider trades and 13F holders, then answers with sources.